Prospect Biosystems focuses on providing biomarker solutions for drug discovery, diagnostics and disease management. The company develops bioanalytical instrumentations, reagents, and biomarker evaluation and validation platforms. Prospect also provides extensive biomarker evaluation and proteomics services.

The Company’s patent-pending Edge™ technology platform is a breakthrough fractionation and separation technology that allows scientists, researchers, and clinicians to rapidly separate highly complex biological samples, enabling them to develop innovative solutions to detect, treat, and manage diseases.

The Edge 200™ Separation System can be used as a standalone instrument or positioned upstream of a wide range of bio-analytical instrumentation such as mass spectrometers, HPLCs, gel electrophoresis, micro-arrays, etc. The Edge 200 does not compete with other systems - it complements and adds value to all downstream bio-analytical processes.

The Company markets and distributes its products and services directly and through distributors and agents worldwide.

Prospect Biosystems was founded in 2006. Its office and laboratory are located at the Enterprise Development Center in Newark, New Jersey, on the campus of New Jersey Institute of Technology.

• Prospect Biosystems' management team
• Meet our collaborators
• Locate a distributor near you
• Join Prospect's team